CFH and non-small cell lung carcinoma: The autoantibodies inhibited CFH binding to lung cancer cells, increased C3b deposition, and induced complement mediated lysis of tumor cells (Campa et al., 2015) and also served as prognostic marker for stage I NSCLC (Gottlin et al., 2022).